Nasdaq

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the United States SALT LAKE CITY, March 17 ...
Business Insider

Myriad Launches riskScore™ Beginning the Next Epoch in Hereditary Cancer TestingProvides Individualized Breast Cancer Risk for Patients Testing Negative with the myRisk ...

SALT LAKE CITY, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that it has launched riskScore ™, a ...
Business Insider

Pioneering genetic-testing company Myriad's biggest up-and-coming product could be at risk after scientists raised major questions

For diseases like depression, finding medications that work well for patients can be a long, arduous journey. Genetic tests now claim to speed it along by giving doctors more information about how ...